 "Laurus Labs falls 5% as promoters sell 1.3% stake in company")
Shares of Laurus Labs were trading 5 per cent lower at Rs 349 on the BSE in intra-day trade on Friday, down 9 per cent from Thursday’s high, after the promoters of the firm sold 1.3 per cent stake in the company for Rs 258 crore via the open market to release pledged shares.
“Dr Satyanarayana Chava, founder promoter, CEO & ED, sold 5.2 million equity shares of the company in the stock market at an average price of Rs 368.59, per share, aggregating to Rs 191.67 crore,” Laurus Labs said in a press release.
The company further said, Nagarani Chava, one of the promoters of the company sold 1.8 million equity shares at an average price of Rs 366.91 per share at an aggregate value of Rs 66.04 crore.
Dr Satyanarayana Chava and Nagarani Chava together sold 7 million equity shares or 1.3 per cent of the paid-up capital of the company. The names of the buyers were not ascertained immediately.
It may be recalled that the above promoters had purchased around 3 per cent of the then paid-up capital of the company in the year 2018, Lauras Labs said.
It added that the significant part of the above amount shall be utilised to release the pledge on the equity shares of the company. As of December 31, 2020, the promoters had pledged 15.76 per cent of the total holdings of 28.76 per cent stake in the company, the shareholding pattern shows.
Laurus Labs is a leading research & development-driven and fully integrated pharmaceutical company in India.
“Dr Satyanarayana Chava, founder promoter, CEO & ED, sold 5.2 million equity shares of the company in the stock market at an average price of Rs 368.59, per share, aggregating to Rs 191.67 crore,” Laurus Labs said in a press release.
The company further said, Nagarani Chava, one of the promoters of the company sold 1.8 million equity shares at an average price of Rs 366.91 per share at an aggregate value of Rs 66.04 crore.
Dr Satyanarayana Chava and Nagarani Chava together sold 7 million equity shares or 1.3 per cent of the paid-up capital of the company. The names of the buyers were not ascertained immediately.
It may be recalled that the above promoters had purchased around 3 per cent of the then paid-up capital of the company in the year 2018, Lauras Labs said.
It added that the significant part of the above amount shall be utilised to release the pledge on the equity shares of the company. As of December 31, 2020, the promoters had pledged 15.76 per cent of the total holdings of 28.76 per cent stake in the company, the shareholding pattern shows.
Laurus Labs is a leading research & development-driven and fully integrated pharmaceutical company in India.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%